Keith D. Lindor, MD
Dean, College of Health Solutions
Dr. Keith D. Lindor believes we must take a holistic approach to the changing scope of the health industry. As dean of the College of Health Solutions, he is working collaboratively with university and industry partners to create and deliver academic offerings that will better prepare the next generation of health professionals to lead change in the context of a quickly evolving health care system. His work’s emphasis is on health as well as health care, with a focus on developing new interprofessional delivery models that improve health outcomes, enhance access and lower costs. Before joining ASU in 2012, Lindor served as dean of the Mayo Medical School and was a professor of medicine and chair in the Division of Gastroenterology and Hepatology. He is recognized as an international authority on cholestatic liver disease, was former editor in chief of the preeminent journal, Hepatology, and is the president of the American Association for the Study of Liver Diseases. Lindor received his medical degree from Mayo Medical School.
- MD - Mayo Medical School, MN, 1979
- BS - University of Minnesota, MN, 1975
- Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. [Review]. Lancet. 2013 Nov.; 382(9904):1587-1599. PMID: 23810223. DOI: 10.1016/S0140-6736(13)60096-3. (Peer-reviewed Article)
- Silveria MG, Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opinion on Pharmachotherapy. 2014 Feb.; 15(3): 365-372. PMID: 24382005. DOI: 10.1517/14656566.2014.873404. (Peer-reviewed Article)
- Gossard AA, Lindor KD. Hepatocellular Carcinoma: Low risk of HCC in patients who have PSC and cirrhosis. Nature Reviews Gastroenterology & Hepatology. 2014 May; 11: 276-277. DOI: 10.1038/nrgastro.2014.470 (Editorial)
- Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA. Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Ann Hepatol. 2014 May-Jun.; 13(3): 384-389. PMID: 24756015. (Peer-reviewed Article)
- Ali AH, Carey EJ, Lindor KD. An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis. Expert Opinion on Orphan Drugs. 2014 Jun; 2(6):545-556. DOI: 10.1517/21678707.2014.908701. (Peer-reviewed Article)
- Tabiban JH, Gossard A, El-Youssef M, Eaton JE, Petz J, Jorgensen R, Enders FB, Tabibian A, Lindor KD. Prospective Clinical trial of Rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther. Epub 2014 Jun 9. PMID: 24914504. (Peer-reviewed Article)
- Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultrcrantz R, Hagstrom H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Haflioadottir S, Bjornsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, et al. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Med. 2014 Jul; 11(7):e1001680. DOI: 10.1371/journal.pmed.1001680. (Peer-reviewed Article)
- Tabibian JH, O’Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol. 2014 Aug; 49(8): 901-908. PMID: 24990660. DOI: 10.3109/00365521.2014.913189. (Peer-reviewed Article)
- Imam MH, Lindor KD. The natural history of primary biliary cirrhosis. Semin Liver Dis. 2014 Aug.; 34(3): 329-333. PMID 25057955. DOI: 10.1055/s-0034-1383731. (Peer-reviewed Article)
- Carey EJ, Lindor KD, Editors. Cholestatic Liver Disease Second Edition. New York: Springer Science + Business Media, 2014. (Book)
- Carey EJ, Lindor KD. Question 29: My Patient Has Primary Sclerosing Cholangitis and Ulcerative Colitis. Is There A Role for Ursodeoxycholic Acid Anymore? In: Rubin DT, Friedman S, Farraye F editor. Curbside Consulation in IBD: 49 Clinical Questions. 2nd Edition. Thorofare: SLACK Inc; 2015. P. 133-135. (Book Chapter).
Recent Grants and Projects
- Multicentered Randomized Trial of High-dose Urso in PSC (Principal Investigator). Funded by National Institute of Diabetes and Digestive and Kidney Diseases, August 2007-July 2013 (R01 DK 56924).
- A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO, UDCA) in Patients with Primary Biliary Cirrhosis (Principal Investigator). Funded by Intercept, October 2007-December 2009.
- Rochester Education and Advocacy for Community Health (REACH). Funded by Pfizer Inc, May 2009-April 2012.
- Modafinil in the Treatment of Fatigue in Patients with Primary Biliary Cirrhosis (Principal Investigator). Funded by American College of Gastroenterology, July 2009-September 2010.
- Prognosis of Nonalcoholic Fatty Liver Disease (Principal Investigator). Funded by National Institute of Diabetes and Digestive and Kidney Diseases, September 2009-August 2013 (R01 DK 82426).
- Antibiotic treatment in Patients with PSC (Principal Investigator). Funded by PSC Partners Seeking A Cure Foundation, January 2010-December 2011.
- Combination therapy with All-trans Retinoic Acid (ATRA) and Ursodeoxycholic acid (UDCA) in Primary Sclerosing Cholangitis (PSC) – Human Pilot Study. Funded by Yale University, November 2011-November 2013.
- Carol M. Gatton Professor of Digestive Disease Research, Mayo Clinic, 2010
- Outstanding Mentorship, Department of Internal Medicine, Mayo Clinic, 2009
- Internal Named Professor - Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, 2007
- MacMillan Management Scholar, Mayo Clinic, 2000